| Literature DB >> 25990361 |
Hadas Ofer-Friedman1, Coral Shefler2, Sarit Sharma3, Amit Tirosh4, Ruthy Tal-Jasper2, Deepthi Kandipalli3, Shruti Sharma3, Pradeep Bathina3, Tamir Kaplansky1, Moran Maskit1, Tal Azouri1, Tsilia Lazarovitch5, Ronit Zaidenstein4, Keith S Kaye3, Dror Marchaim1.
Abstract
A recent, frequently quoted study has suggested that for bloodstream infections (BSIs) due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) Escherichia coli, treatment with β-lactam/β-lactamase inhibitors (BLBLIs) might be equivalent to treatment with carbapenems. However, the majority of BSIs originate from the urinary tract. A multicenter, multinational efficacy analysis was conducted from 2010 to 2012 to compare outcomes of patients with non-urinary ESBL BSIs who received a carbapenem (69 patients) vs those treated with piperacillin-tazobactam (10 patients). In multivariate analysis, therapy with piperacillin-tazobactam was associated with increased 90-day mortality (adjusted odds ratio, 7.9, P=.03). For ESBL BSIs of a non-urinary origin, carbapenems should be considered a superior treatment to BLBLIs.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25990361 DOI： 10.1017/ice.2015.101
Source DB: PubMed Journal: Infect Control Hosp Epidemiol ISSN： 0899-823X Impact factor: 3.254